Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: A randomized, double-blind, placebo-controlled study

Current Medical Research and Opinion

Volumn 28, Issue 5, 2012, Pages 859-870

  Rauck, Richard ^a   Reynolds, Lowell ^b   Geach, Jonathan ^b   Bull, Janet ^c   Stearns, Lisa ^d   Scherlis, Morris ^e   Parikh, Neha ^f   Dillaha, Larry ^f  

^a Center for Clinical Research   (United States)

^b LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Four Seasons Hospice and Palliative Care   (United States)

^d Center for Pain and Supportive Care   (United States)

^e Tenessee Valley Pain Consultants   (United States)

^f Insys Therapeutics Inc   (United States)

Author keywords

Breakthrough pain; Cancer; Fentanyl; Opioid; Spray; Sublingual

Indexed keywords

FENTANYL; PLACEBO;

ADULT; AGED; ANALGESIA; ARTICLE; BREAKTHROUGH CANCER PAIN; CANCER PAIN; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; HUMAN; HYPERHIDROSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; VOMITING;

ADMINISTRATION, SUBLINGUAL; AGED; ANALGESICS, OPIOID; DOUBLE-BLIND METHOD; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PAIN; PAIN MEASUREMENT; TREATMENT OUTCOME;

EID: 84861120406     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.683111     Document Type: Article

References (32)

1. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-81 (Pubitemid 20187930)
2. Portenoy RK, Payne D, et al. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999;81:129-34 (Pubitemid 29199908)
3. Portenoy RK, Bruns D, Shoemaker et al. Breakthrough pain in communitydwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics. J Opioid Manag 2010;6:97-108
4. Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 2005;9:195-206 (Pubitemid 40311842)
5. Portenoy RK, Bruns D, Shoemaker B, et al. Breakthrough pain in communitydwelling patients with cancer pain and noncancer pain, part 2: impact on function, mood, and quality of life. J Opioid Manag 2010;6:109-16
6. Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 2004;18:177-83 (Pubitemid 38771657)
7. William L, Macleod R. Management of breakthrough pain in patients with cancer. Drugs 2008;68:913-24 (Pubitemid 351652921)
8. Fishbain DA. Pharmacotherapeutic management of breakthrough pain in patients with chronic persistent pain. Am J Manag Care 2008;14(5 Suppl 1):S123-8 (Pubitemid 351786786)
9. Porta-Sales J. From morphine to fentanyl: a review of opioid drugs for BTcP management. Eur J Palliat Care 2010;17(Suppl 3):20-4
10. Anderson R, Saiers JH, Abram S, et al. Accuracy in equianalgesic dosing: conversion dilemmas. J Pain Symptom Manage 2001;21:397-406 (Pubitemid 32452140)
11. Pereira J, Lawlor P, Vigano A, et al. Equianalgesic dose ratios for opioids: a critical review and proposals for long-term dosing. J Pain Symptom Manage 2001;22:672-87 (Pubitemid 32725810)
12. Prommer E. The role of fentanyl in cancer-related pain. J Palliat Med 2009;12:947-54
13. Stevens RA, Ghazi SM. Routes of opioid analgesic therapy in the management of cancer pain. Cancer Control 2000;7:132-41 (Pubitemid 30196850)
14. Portenoy RK, Payne R, Coluzzi P, et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999;79:303-12 (Pubitemid 29076765)
15. Christie JM, Simmonds M, Patt R, et al. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 1998;16:3238-45 (Pubitemid 28481617)
16. Payne R, Coluzzi P, Hart L, et al. Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manage 2001;22:575-83 (Pubitemid 32547445)
17. Rauck R, North J, Gever LN, et al. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol 2010;21:1308-14
18. Rauck RL, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 2009;25:2877-85
19. Portenoy RK, Taylor D, Messina J, et al. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006;22:805-11 (Pubitemid 44627444)
20. Weinstein SM, Messina J, Xie F. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: a long-term, open-label safety study. Cancer 2009;115:2571-9
21. Nalamachu S, Hassman D, Wallace MS, et al. Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain. Curr Med Res Opin 2011;27:519-30
22. Harris D, Robinson JR. Drug delivery via the mucous membranes of the oral cavity. J Pharm Sci 1992;81:1-10
23. Pimlott SJ, Addy M. Evaluation of a method to study the uptake of prednisolone sodium phosphate from different oral mucosal sites. Oral Surg Oral Med Oral Pathol 1985;60:35-7 (Pubitemid 15048644)
24. Pimlott SJ, Addy M. A study into the mucosal absorption of isosorbide dinitrate at different intraoral sites. Oral Surg Oral Med Oral Pathol 1985;59:145-8 (Pubitemid 15046960)
25. Shojaei AH. Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharm Sci 1998;1:15-30
26. Narang N, Sharma J. Sublingual mucosa as a route for systemic drug delivery. Int J Pharm Pharm Sci 2011;3(Suppl 2):18-22
27. Weinberg DS, Inturrisi CE, Reidenberg B, et al. Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 1988;44:335-42
28. Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004;2:12
29. Atkinson MJ, Kumar R, Cappelleri JC, et al. Hierarchical construct validity of the Treatment Satisfaction Questionnaire for Medication (TSQM version II) among outpatient pharmacy consumers. Value Health 2005;8(Suppl 1):S9-24
30. Hochberg Y. A sharper Bonferroni procedure for multiple significance testing. Biometrika 1988;75:800-3
31. Farrar JT, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998;90:611-16 (Pubitemid 28204805)
32. Slatkin NE, Xie F, Messina J, et al. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 2007;5:327-34 (Pubitemid 350055013)